Clinical Trial

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

Study acronym: Firecrest
Completed Phase 2/3
View on ClinicalTrials.gov →
Summary
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Protocol Amendment History 3 changes
critical Trial completed 2026-07-30
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-07
notable Enrollment increased: 36 -> 60 participants 2026-04-04
Trial Details
NCT Number NCT07354516
Lead Sponsor Qlaris Bio, Inc.
Conditions OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Enrollment 64 participants
Start Date 2026-03-18
Primary Completion 2026-07-22 (estimated)
Study Completion 2026-07-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-29